GLI Supports the Reintroduction of the Treat and Reduce Obesity Act

(Washington, D.C., June 9, 2025) – Global Liver Institute (GLI) applauds the reintroduction of the bipartisan Treat and Reduce Obesity Act, which was recently introduced by Senators Bill Cassidy (R-LA) and Ben Ray Luján (D-NM). Within both the political and scientific realms, there is growing recognition of obesity as a chronic disease and the need to address and treat obesity like any other chronic disease. A robust body of research demonstrates the connection between obesity and serious liver diseases, such as nonalcoholic steatohepatitis (NASH), making access to treatment a top priority for GLI and patients. 

Globally, NASH affects more than 148 million people and continues to become more prevalent each year. With the expectation that 1 in 4 individuals will be obese by 2035, it is crucial that we utilize unbiased and science-based approaches to both NASH and obesity care. GLI closely aligns with the obesity advocacy community in recognizing obesity as a serious and complex condition. By addressing obesity, there is a path to prevent chronic diseases, including NASH.  

This bipartisan legislation would expand coverage of new health care specialists and chronic weight management medications for Medicare recipients. It will also work to mitigate the obesity epidemic by providing regular screenings.

GLI will continue to support and advocate for patients, both in treating liver diseases and in preventing liver diseases.

About Global Liver Institute  

Global Liver Institute (GLI) is a 501(c)3 nonprofit organization founded in the belief that liver health must take its place on the global public health agenda commensurate with the prevalence and impact of liver illness. GLI promotes innovation, encourages collaboration, and supports the scaling of optimal approaches to help eradicate liver diseases. Operating globally, GLI is committed to solving the problems that matter to liver patients and equipping advocates to improve the lives of individuals and families impacted by liver disease. GLI holds Platinum Transparency with Candid/GuideStar, is a member of the National Health Council, and serves as a Healthy People 2030 Champion. Follow GLI on Facebook, Instagram, LinkedIn, and YouTube or visit www.globalliver.org.